The Strategy of Immunologic Control of HIV-1 with Structured Treatment Interruptions (STIs)
Current Drug Target -Infectious Disorders · 2001
DOI: 10.2174/1568005013343236 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Drug Target -Infectious Disorders, 2001. Verfasst von R B Moss und 3 weiteren Autor:innen. Beteiligte Einrichtung: Immune Response Corporation, 5935 Darwin Court, Carlsbad, CA 92008, USA. Hauptthemen laut MEDLINE: Antiretroviral Therapy, Highly Active. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Immune Response Corporation, 5935 Darwin Court, Carlsbad, CA 92008, USA.
Zitieren
APA
Moss, R. B., Jensen, F. C., Carlo, D. J., & Wallace, M. R. (2001). The Strategy of Immunologic Control of HIV-1 with Structured Treatment Interruptions (STIs). Current Drug Target -Infectious Disorders. https://doi.org/10.2174/1568005013343236
Vancouver
Moss RB, Jensen FC, Carlo DJ, Wallace MR. The Strategy of Immunologic Control of HIV-1 with Structured Treatment Interruptions (STIs). Current Drug Target -Infectious Disorders. 2001. doi:10.2174/1568005013343236
BibTeX
@article{Moss2001,
author = {Moss, R B and Jensen, F C and Carlo, D J and Wallace, M R},
title = {The Strategy of Immunologic Control of HIV-1 with Structured Treatment Interruptions (STIs)},
journal = {Current Drug Target -Infectious Disorders},
year = {2001},
doi = {10.2174/1568005013343236}
}
EUVIMED